Patents by Inventor Nurit Rachamim

Nurit Rachamim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Humanized Antibodies to Cluster of Differentiation 3 (CD3)
    Publication number: 20180244778
    Abstract: Humanized monoclonal antibodies (mAbs) or fragments thereof, to human Cluster of Differentiation 3 (CD3), which confer improved immune stimulation and stability, are disclosed. Pharmaceutical compositions comprising said mAbs and methods of treatment and optionally also prevention of diseases and disorders, such as autoimmune disorders, infectious diseases, and transplant rejection, that are susceptible to amelioration by binding to CD3, are also disclosed.
    Type: Application
    Filed: May 14, 2018
    Publication date: August 30, 2018
    Inventors: Ronald Ellis, Michael Tal, Sarit Samira, Nurit Rachamim, Timothy David Jones, Francis Joseph Carr, Shahar Dotan
  • Humanized antibodies to cluster of differentiation 3 (CD3)
    Patent number: 10000567
    Abstract: Humanized monoclonal antibodies (mAbs) or fragments thereof, to human Cluster of Differentiation 3 (CD3), which confer improved immune stimulation and stability, are disclosed. Pharmaceutical compositions comprising said mAbs and methods of treatment and optionally also prevention of diseases and disorders, such as autoimmune disorders, infectious diseases, and transplant rejection, that are susceptible to amelioration by binding to CD3, are also disclosed.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: June 19, 2018
    Assignee: Therapix Biosciences Ltd.
    Inventors: Ronald Ellis, Michael Tal, Sarit Samira, Nurit Rachamim, Timothy David Jones, Francis Joseph Carr, Shahar Dotan
  • Methods and compositions with immune therapy for treatment of dementia
    Patent number: 9879076
    Abstract: Novel antibodies, methods and compositions for treatment of a disease which is susceptible to amelioration by the blocking of APP cleavage.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: January 30, 2018
    Assignee: RAMOT AT TEL AVIV UNIVERSITY LTD.
    Inventors: Sarit Samira, Nurit Rachamim, Michael Tal, Ronald Ellis, Idan Rakover, Rom E. Eliaz, Beka Solomon, Timothy David Jones, Francis Joseph Carr, Polina Rabinovich-Toidman, Meital Sooliman
  • METHODS AND COMPOSITIONS WITH IMMUNE THERAPY FOR TREATMENT OF DEMENTIA
    Publication number: 20160017025
    Abstract: Novel antibodies, methods and compositions for treatment of a disease which is susceptible to amelioration by the blocking of APP cleavage.
    Type: Application
    Filed: March 13, 2014
    Publication date: January 21, 2016
    Inventors: Sarit SAMIRA, Nurit RACHAMIM, Michael TAL, Ronald ELLIS, Idan RAKOVER, Rom E. ELIAZ, Beka SOLOMON, Timothy David JONES, Francis Joseph CARR, Polina RABINOVICH-TOIDMAN, Meital SOOLIMAN
  • HUMANIZED ANTIBODIES TO CLUSTER OF DIFFERENTIATION 3 (CD3)
    Publication number: 20150175699
    Abstract: Humanized monoclonal antibodies (mAbs) or fragments thereof, to human Cluster of Differentiation 3 (CD3), which confer improved immune stimulation and stability, are disclosed. Pharmaceutical compositions comprising said mAbs and methods of treatment and optionally also prevention of diseases and disorders, such as autoimmune disorders, infectious diseases, and transplant rejection, that are susceptible to amelioration by binding to CD3, are also disclosed.
    Type: Application
    Filed: March 12, 2013
    Publication date: June 25, 2015
    Inventors: Ronald Ellis, Michael Tal, Sarit Samira, Nurit Rachamim, Timothy David Jones, Francis Joseph Carr, Shahar Dotan
  • Antibodies against flagellin and uses thereof
    Patent number: 8263078
    Abstract: The present invention provides a novel class of monoclonal antibodies which have a high affinity, broad spectrum neutralizing reactivity to flagellin from various Gram-negative bacteria including, but not limited to, E. coli, Salmonella, Serratia, Proteus, Enterobacter, Citrobacter, Campylobacter and Pseudomonas. The present invention further provides methods of treating inflammatory bowel disease (IBD) and methods of treating enterobacterial infections using anti-flagellin antibodies in humans, other animals and birds.
    Type: Grant
    Filed: September 5, 2008
    Date of Patent: September 11, 2012
    Assignees: Inotek Pharmaceuticals Corporation, Yeda Research and Development Co., Ltd.
    Inventors: Nurit Rachamim, Andrew L. Salzman, Kanneganti Murthy
  • Antibodies against flagellin and uses thereof
    Publication number: 20090208506
    Abstract: The present invention provides a novel class of monoclonal antibodies which have a high affinity, broad spectrum neutralizing reactivity to flagellin from various Gram-negative bacteria including, but not limited to, E. coli, Salmonella, Serratia, Proteus, Enterobacter, Citrobacter, Campylobacter and Pseudomonas. The present invention further provides methods of treating inflammatory bowel disease (IBD) and methods of treating enterobacterial infections using anti-flagellin antibodies in humans, other animals and birds.
    Type: Application
    Filed: September 5, 2008
    Publication date: August 20, 2009
    Applicants: Inotek Pharmaceuticals Corporation, Yeda Research and Development Co., Ltd.
    Inventors: Nurit Rachamim, Andrew L. Salzman, Kanneganti Murthy